International external quality assurance of JAK2 V617F quantification.

Autor: Asp J; Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. julia.asp@gu.se., Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Bellosillo B; Department of Pathology, Hospital del Mar, Barcelona, Spain., Kristensen T; Department of Pathology, Odense University Hospital, Odense, Denmark., Lippert E; CHU de Brest, Brest, France., Dicker F; Munich Leukemia Laboratory, Munich, Germany., Schwarz J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Wojtaszewska M; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland., Palmqvist L; Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Akiki S; Department of Laboratory Medicine and Pathology, Qatar Rehabilitation Institute (QRI), Hamad Bin Khalifa Medical City (HBKM), Doha, Qatar., Aggerholm A; Aarhus University Hospital, Aarhus, Denmark., Tolstrup Andersen M; Rigshospitalet, Copenhagen, Denmark., Girodon F; CHU Dijon/INSERM U866, Dijon, France., Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Oppliger Leibundgut E; University Hospital Bern and University of Bern, Bern, Switzerland., Pancrazzi A; Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Florence, Italy., Vorland M; Haukeland University Hospital, Bergen, Norway., Andrikovics H; Central Hospital of Southern Pest, Budapest, Hungary., Kralovics R; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, and Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Cassinat B; Service de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France., Coucelo M; Clinical Hematology Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal., Eftimov A; Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, UKiM, Skopje, Republic of Macedonia., Haslam K; St James's Hospital, Dublin, Ireland., Kusec R; Dubrava University Hospital and Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia., Link-Lenczowska D; Molecular Diagnostics Laboratory, Hematology Diagnostics Department, Jagiellonian University Hospital, Krakow, Poland., Lodé L; Hématologie Biologique, CHRU de Montpellier, Montpellier, France., Matiakowska K; Faculty of Medicine, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland., Naguib D; CHU Côte de Nacre, Caen, France., Navaglia F; Department of Laboratory Medicine, University - Hospital of Padova, Padova, Italy., Novotny GW; Department of Hematology and Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730, Herlev, Denmark., Percy MJ; Belfast City Hospital, Belfast, UK., Sudarikov A; National Research Center for Hematology, Moscow, Russia., Hermouet S; Laboratory of Hematology, University Hospital (CHU) Nantes, Nantes, France.; CRCINA, Inserm UMR892 / CNRS UMR6299, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université de Nantes, Nantes, France., Pallisgaard N; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2019 May; Vol. 98 (5), pp. 1111-1118. Date of Electronic Publication: 2018 Dec 08.
DOI: 10.1007/s00277-018-3570-8
Abstrakt: External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is important that EQA for quantitative analysis takes into account the variation in methodology. Results cannot be expected to be more accurate than limits of the technology used, and it is essential to recognize factors causing substantial outlier results. The present study aimed to identify parameters of specific importance for JAK2 V617F quantification by quantitative PCR, using different starting materials, assays, and technical platforms. Sixteen samples were issued to participating laboratories in two EQA rounds. In the first round, 19 laboratories from 11 European countries analyzing JAK2 V617F as part of their routine diagnostics returned results from in-house assays. In the second round, 25 laboratories from 17 countries participated. Despite variations in starting material, assay set-up and instrumentation the laboratories were generally well aligned in the EQA program. However, EQA based on a single technology appears to be a valuable tool to achieve standardization of the quantification of JAK2 V617F allelic burden.
Databáze: MEDLINE
Externí odkaz: